ArticleJournal of inflammation research2026
TUDCA-3S is Associated with Acute Pancreatitis Severity and Pro-Inflammatory Macrophage Activation Involving S100A8/IL-17 Signaling.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Early identification of patients at risk of severe acute pancreatitis (SAP) remains challenging, and the contribution of sulfated bile-acid metabolites to AP-associated inflammatory responses remains incompletely understood. This study investigated the association between serum TUDCA-3S and AP severity and explored its effects on inflammatory macrophage activation in vitro. Methods: The study cohort comprised 100 patients with acute pancreatitis (AP) and 50 healthy controls. Serum TUDCA-3S levels were quantified using targeted metabolomics, and associations with disease severity and receiver operating characteristic (ROC) performance were evaluated. An LPS-stimulated RAW264.7 inflammatory macrophage model was used to examine cellular responses associated with TUDCA-3S exposure. Flow cytometry, RT-qPCR, Western blotting, transcriptomics, untargeted metabolomics, lipidomics, and S100A8 knockdown were used for further characterization. Results: Serum TUDCA-3S levels differed significantly among the study groups, with the highest median level observed in patients with SAP. TUDCA-3S distinguished AP patients from healthy controls with an AUC of 0.873. However, its performance for severity discrimination was substantially lower, with an AUC of 0.534 for MAP versus MSAP and 0.714 for MAP/MSAP versus SAP. In LPS-stimulated RAW264.7 macrophages, TUDCA-3S exposure was associated with enhanced M1-related inflammatory features and increased S100A8 and IL-17A expression. S100A8 knockdown attenuated M1-associated markers and IL-17A expression. Transcriptomic, untargeted metabolomic, and lipidomic analyses further identified inflammatory and lipid-metabolic changes associated with TUDCA-3S exposure. Conclusion: Serum TUDCA-3S is associated with AP and disease severity, although its discriminatory performance across AP severity categories is limited to moderate. The in vitro findings support an association between TUDCA-3S exposure and pro-inflammatory macrophage features involving S100A8-associated IL-17A signaling and metabolic remodeling. These findings are exploratory and require independent clinical and experimental validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.